<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-90909" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Digoxin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>David</surname>
            <given-names>Marie Nicole V.</given-names>
          </name>
          <aff>Universit&#x000e9; Notre Dame d&#x02019;Haiti facult&#x000e9; de m&#x000e9;decine et des sciences de la sant&#x000e9;</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shetty</surname>
            <given-names>Mrin</given-names>
          </name>
          <aff>University of Chicago (NorthShore)</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marie Nicole David declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mrin Shetty declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-90909.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Digoxin is a medication used to manage and treat heart failure, certain arrhythmias, and abortion. It is in the cardiac glycoside class of drugs. This article outlines the indications, actions, and contraindications for digoxin as a valuable agent in managing heart failure and certain arrhythmias. This activity will highlight the mechanism of action, toxicity profile, and other vital factors, eg, dosing, pharmacodynamics, pharmacokinetics, and monitoring, pertinent for members of the healthcare team in the management of patients who have been prescribed digoxin.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the select patient population who would benefit from digoxin therapy.</p></list-item><list-item><p>Summarize the potential adverse effects of digoxin therapy.</p></list-item><list-item><p>Identify the typical presentation of digoxin toxicity.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interdisciplinary team to enhance care delivery for patients receiving digoxin therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=90909&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=90909">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-90909.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Digoxin comes from the foxgloves plant known as <italic toggle="yes">Digitalis lanata</italic>. It is a cardiotonic glycoside and belongs to the digitalis class. The chemical formula of digoxin is C41 H64 O14. Cardiac glycosides, including digitalis and digoxin, have long-standing use in clinical practice. This drug received approval from the United States Food and Drug Administration in 1954 and is used to treat various heart problems such as atrial flutter, atrial fibrillation, and heart failure with its associated symptoms and to induce fetal demise prior to an abortion. Superior therapies with milder adverse effects and better safety profiles, such as beta-blockers and calcium-channel blockers, have replaced it. In current practice, it is reserved as a backup drug when first-line agents are ineffective. Its optimal use is in the treatment of mild to moderate heart failure in adult patients and to increase myocardial contraction.</p>
        <p>Digoxin is beneficial in patients with systolic heart failure, better known as heart failure with reduced ejection fraction, with an ejection fraction below 40%.<xref ref-type="bibr" rid="article-90909.r1">[1]</xref>&#x000a0;However, it has no benefit in mortality reduction. It is used for rate control in atrial fibrillation or atrial flutter when conventional therapies have not achieved the heart rate goal. Digoxin should not be administered in cases of pre-excitation caused by accessory pathways, as digoxin induces AV blockade and may trigger ventricular tachyarrythmias. It is ineffective in states of high sympathetic activity. Beta-blockers are preferable in such cases. Supraventricular tachycardias not rate controlled by traditional therapies may benefit from digoxin. Digoxin use has shown some success in the treatment of fetal supraventricular tachyarrhythmia. The lowest effective dose should be administered to the mother as digoxin might cause uterine contractions and result in abortion.</p>
      </sec>
      <sec id="article-90909.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Digoxin has 2 principal mechanisms of action, which are selectively employed depending on the indication:</p>
        <list list-type="order">
          <list-item>
            <p>Positive ionotropic: It increases the force of contraction of the heart by reversibly inhibiting the activity of the myocardial sodium=potassium adenosinetriphosphatase pump, an enzyme that controls the movement of ions into the heart. Digoxin induces an increase in intracellular sodium that will drive an influx of calcium in the heart and cause an increase in contractility. Cardiac output increases with a subsequent decrease in ventricular filling pressures.<xref ref-type="bibr" rid="article-90909.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>AV node inhibition: Digoxin has vagomimetic effects on the AV node. By stimulating the parasympathetic nervous system, it slows electrical conduction in the atrioventricular node, therefore decreasing the heart rate. The rise in calcium levels leads to the prolongation of phase 4 and phase 0 of the cardiac action potential, thus increasing the AV node's refractory period. Slower conduction through the AV node carries a decreased ventricular response.<xref ref-type="bibr" rid="article-90909.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>Another use of digoxin is to induce fetal death before a second-trimester abortion. Digoxin kills the cells and poisons the tissues of the fetus. The kidneys excrete digoxin in direct proportion to the glomerular filtration rate; the liver metabolizes 16%. Digoxin has a half-life that varies from 36 to 48 hours, which may increase in cases of renal failure.<xref ref-type="bibr" rid="article-90909.r3">[3]</xref></p>
      </sec>
      <sec id="article-90909.s4" sec-type="Administration">
        <title>Administration</title>
        <p>It is best to administer digoxin intravenously to achieve rapid digitalization. Intramuscular injections are highly discussed. No more than 2 mL of the drug should be injected at the same site. The injection should be made deep into the muscle, and the overlying area should be massaged post-injection. Intravenous injections are metabolized more efficiently than intramuscular injections and are the preferred route, as only about 80% of the drug is absorbed in intra-muscular injections compared to intravenous dosing. There is a risk of local irritation or myonecrosis.</p>
        <p>Digoxin has an oral bioavailability of approximately 75%, although intake efficacy might diminish when taking digoxin with high-fiber foods. Some patients possess gut flora that metabolizes digoxin to dihydrodigoxin, decreasing the drug's absorption. Macrolides interfere with normal gut microbiota, which normally metabolizes digoxin and can lead to higher absorbed concentrations. Metoclopramide decreases digoxin absorption. Indomethacin and spironolactone decrease the clearance of the drug.&#x000a0;</p>
        <p>Important considerations during administration include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Requesting an electrocardiogram before digoxin administration is important. &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Electrolytes, mainly potassium levels, must be assessed and normalized before digoxin administration.</p>
          </list-item>
          <list-item>
            <p>If bradycardia is present, re-evaluate and withhold treatment as necessary.<xref ref-type="bibr" rid="article-90909.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>Clinical staff should monitor the plasma digoxin level at least 6 or 12 hours post-administration of the last loading dose, as this is the time to achieve steady-state levels. The recommended thresholds of therapeutic serum digoxin levels are 0.5&#x000a0;to 2 ng/mL.</p>
      </sec>
      <sec id="article-90909.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Digoxin toxicity is clinically relevant as it can lead to fatal cardiac arrhythmias. The estimated frequency is about 0.8&#x000a0;to 4% of patients on steady digoxin therapy. The rate of toxicity increases as serum digoxin concentration reaches over 2.0 ng/mL. However, toxicity can also occur at lower levels, especially in the setting of other risk factors such as low body weight, advanced age, decreased renal function, and hypokalemia.</p>
        <p>Symptoms may be mild and include nausea, vomiting, and anorexia. Visual side effects might include color changes, also known as xanthopsia. However, yellow or green-tinted vision is usually associated with digoxin toxicity. Patients may also highlight blurry vision or photopsia. At toxic levels, digoxin is proarrhythmic. An impaired ventricle is more prone to ventricular tachyarrhythmias and ectopy. Abnormally high digoxin levels stimulate atrial activation; thus, atrial tachycardias in a patient on digoxin is highly suggestive of toxicity. These atrial tachycardias are persistent and resolve with a decrease in serum digoxin levels.</p>
        <p>Other common side effects include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Rash</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Gynecomastia</p>
          </list-item>
          <list-item>
            <p>Weakness</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-90909.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Digoxin is contraindicated&#x000a0;in the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute myocardial infarction</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity to the drug</p>
          </list-item>
          <list-item>
            <p>Ventricular fibrillation</p>
          </list-item>
          <list-item>
            <p>Myocarditis</p>
          </list-item>
          <list-item>
            <p>Hypomagnesemia</p>
          </list-item>
          <list-item>
            <p>Hypokalemia</p>
          </list-item>
          <list-item>
            <p>Wolf-Parkinson-White syndrome&#x000a0;<xref ref-type="bibr" rid="article-90909.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>Its use requires caution in cases of:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypercalcemia/hypocalcemia</p>
          </list-item>
          <list-item>
            <p>Renal impairment</p>
          </list-item>
          <list-item>
            <p>Diseased SA node</p>
          </list-item>
          <list-item>
            <p>Bradycardia</p>
          </list-item>
          <list-item>
            <p>AV block</p>
          </list-item>
          <list-item>
            <p>Restrictive cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Constrictive pericarditis</p>
          </list-item>
          <list-item>
            <p>Thyroid disease: hypothyroidism leads to delayed drug clearance; hyperthyroidism does the opposite</p>
          </list-item>
        </list>
        <p>Digoxin may present interactions with the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Azole antifungals,&#x000a0;which inhibit the transport of digoxin via human P-glycoprotein</p>
          </list-item>
          <list-item>
            <p>Macrolide antibiotics inhibit P-glycoprotein, thus increasing intestinal drug absorption</p>
          </list-item>
          <list-item>
            <p>Rifampin</p>
          </list-item>
          <list-item>
            <p>Dronedarone</p>
          </list-item>
          <list-item>
            <p>Loop diuretics</p>
          </list-item>
          <list-item>
            <p>Quinidine</p>
          </list-item>
          <list-item>
            <p>Intravenous calcium products</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-90909.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Digoxin has a narrow therapeutic index. The recommended serum levels stand between 0.8&#x000a0;to 2 ng/mL.<xref ref-type="bibr" rid="article-90909.r6">[6]</xref>&#x000a0;When measuring a digoxin serum level, drawing blood at least 6 to 8 hours after the last dose is essential. The toxicity increases as the serum drug levels increase&#x000a0;above 2.0 ng/mL. The prescriber needs to check levels with any recent change in medication. The kidneys excrete approximately 70% of digoxin in direct proportion to the patient's glomerular filtration rate. The physician must request regular electrocardiograms and bloodwork to assess renal function; electrolytes require close monitoring.<xref ref-type="bibr" rid="article-90909.r7">[7]</xref>&#x000a0;Digoxin levels should be checked one week after starting the medication and regularly afterward.&#x000a0;</p>
        <p>Electrocardiogram changes seen with digoxin demonstrate a downsloping ST-segment depression, also known as a "reverse check" sign. The ST segments may appear "scooped" without abnormal Q waves or T wave inversions.<xref ref-type="bibr" rid="article-90909.r8">[8]</xref> Regular intake of digoxin results in decreased QT interval, prolongation of the PR interval, and T wave inversion or flattening. In the case of an overdose, the patient should receive digoxin immune fab. This molecule binds to the digoxin, making it unable to bind to its active sites.&#x000a0;Digoxin immune fab use requires&#x000a0;caution&#x000a0;because reversing the effects of digoxin will reduce serum potassium levels.</p>
      </sec>
      <sec id="article-90909.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Overdose of digoxin may provoke troublesome arrhythmias or malignant hyperkalemia.<xref ref-type="bibr" rid="article-90909.r8">[8]</xref>&#x000a0;The association between digoxin use and mortality has raised many concerns among researchers, as there is some evidence that it seems to increase mortality risks. Digoxin has a very narrow therapeutic index, and its administration is subject to drug-drug interactions and comorbidities. In the case of an overdose, digoxin immune fab is the reversal agent.</p>
        <p>The following conditions indicate the use of digoxin immune fab:</p>
        <list list-type="bullet">
          <list-item>
            <p>Any digoxin-related life-threatening dysrhythmia</p>
          </list-item>
          <list-item>
            <p>Refractory hyperkalemia</p>
          </list-item>
          <list-item>
            <p>Serum digoxin concentration over 15 ng/mL at any time&#x000a0;or above 10 ng/mL 6 hours post-ingestion</p>
          </list-item>
          <list-item>
            <p>Acute ingestion of 10 mg in adults</p>
          </list-item>
          <list-item>
            <p>Acute ingestion of 4 mg in children</p>
          </list-item>
          <list-item>
            <p>Chronic elevation of serum digoxin concentration with altered mental status, dysrhythmias, or severe gastrointestinal symptoms</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-90909.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Overdose of digoxin may provoke troublesome arrhythmias and malignant hyperkalemia.&#x000a0;The association between digoxin use and mortality has raised many concerns among researchers. It seems to increase mortality risks. That is why digoxin therapy requires an interprofessional team to prescribe and oversee therapy. This team includes clinicians, specialists, mid-level practitioners, nurses, and pharmacists, all sharing information and coordinating activities to optimize therapy and prevent adverse effects.&#x000a0;</p>
        <p>Digoxin has a very narrow therapeutic index, and its administration is subject to drug-drug interactions and comorbidities. The treatment of digoxin toxicity primarily focuses on supportive therapy with intravenous hydration and electrolyte repletion.<xref ref-type="bibr" rid="article-90909.r9">[9]</xref> It requires the contribution of the medical workforce. Without timely and specific intervention, the patient is at significant risk of dying. If digoxin toxicity is confirmed, after assessing serum blood levels and electrocardiogram, the clinician should:</p>
        <list list-type="bullet">
          <list-item>
            <p>Request pharmacy to provide digoxin immune fab and check the patient medication profile for drug interactions.</p>
          </list-item>
          <list-item>
            <p>Take into account nephrology's input if indications exist for the use of emergent hemodialysis.</p>
          </list-item>
          <list-item>
            <p>Maintain supportive care with intravenous hydration and electrolyte repletion.</p>
          </list-item>
          <list-item>
            <p>Refer the patient to the intensive care unit.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-90909.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=90909&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=90909">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/90909/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=90909">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-90909.s11">
        <title>References</title>
        <ref id="article-90909.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grubb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mentz</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions.</article-title>
            <source>Expert Rev Cardiovasc Ther</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-101</page-range>
            <pub-id pub-id-type="pmid">32066285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90909.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ren</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ribas</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Heath</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shriwas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Burdette</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kinghorn</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Na<sup>+</sup>/K<sup>+</sup>-ATPase-Targeted Cytotoxicity of (+)-Digoxin and Several Semisynthetic Derivatives.</article-title>
            <source>J Nat Prod</source>
            <year>2020</year>
            <month>Mar</month>
            <day>27</day>
            <volume>83</volume>
            <issue>3</issue>
            <fpage>638</fpage>
            <page-range>638-648</page-range>
            <pub-id pub-id-type="pmid">32096998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90909.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lunney</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruospo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Natale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Ronksley</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Konstantinidis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Tonelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Strippoli</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Ravani</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological interventions for heart failure in people with chronic kidney disease.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Feb</month>
            <day>27</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>CD012466</fpage>
            <pub-id pub-id-type="pmid">32103487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90909.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Djohan</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Sia</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Poh</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>A myriad of electrocardiographic findings associated with digoxin use.</article-title>
            <source>Singapore Med J</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-14</page-range>
            <pub-id pub-id-type="pmid">32043160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90909.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fu</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Deleterious cardiovascular effect of exosome in digitalis-treated decompensated congestive heart failure.</article-title>
            <source>J Biochem Mol Toxicol</source>
            <year>2020</year>
            <month>May</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>e22462</fpage>
            <pub-id pub-id-type="pmid">32045083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90909.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mutlu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aslan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kader</surname>
                <given-names>&#x0015e;</given-names>
              </name>
              <name>
                <surname>Akt&#x000fc;rk-Acar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dilber</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Clinical signs and symptoms of toxic serum digoxin levels in neonates.</article-title>
            <source>Turk J Pediatr</source>
            <year>2019</year>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>244</fpage>
            <page-range>244-249</page-range>
            <pub-id pub-id-type="pmid">31951334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90909.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angraal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nuti</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Masoudi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Murugiah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Ranasinghe</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Digoxin Use and Associated Adverse Events Among Older Adults.</article-title>
            <source>Am J Med</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>132</volume>
            <issue>10</issue>
            <fpage>1191</fpage>
            <page-range>1191-1198</page-range>
            <pub-id pub-id-type="pmid">31077654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90909.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Negroni</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Marengo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caruso</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tayar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rubiolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Giavarini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Persampieri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sangiovanni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Davanzo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Carugo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Dell'Agli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A Case Report of Accidental Intoxication following Ingestion of Foxglove Confused with Borage: High Digoxinemia without Major Complications.</article-title>
            <source>Case Rep Cardiol</source>
            <year>2019</year>
            <volume>2019</volume>
            <fpage>9707428</fpage>
            <pub-id pub-id-type="pmid">31871798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90909.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Writing Committee Members</collab>
              <name>
                <surname>Kusumoto</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Schoenfeld</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Edgerton</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Ellenbogen</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Goldschlager</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marine</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Oken</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Patton</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Pellegrini</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Selzman</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Varosy</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>2018 ACC/AHA/HRS guideline on the&#x000a0;evaluation and management of patients with bradycardia and cardiac conduction delay: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society.</article-title>
            <source>Heart Rhythm</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>e227</fpage>
            <page-range>e227-e279</page-range>
            <pub-id pub-id-type="pmid">30412777</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
